CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Trial closures for BR16 (NCT00008385) trial: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer and IND222 ( NCT02619864) A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme.
Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply.
Spring application deadline is March 27, 2020
The CCTG Annual Spring Meeting of Participants is almost here, if you are planning meetings and/or attending the Spring Meeting here is some information you should know!
CCTG Patient Representative Bob Taylor discusses the importance of having somebody, that's not the clinical researcher, representing what patients care about and considering the interests of the patients and their family in clinical trial design.
CCTG has been awarded $1,303,560 from the Fall 2019 CIHR Project Grant competition, a program that helps advance health-related research. The funds will support the Canadian contribution to the ME15 international trial, investigating use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient - Larger margins result in disfigurement, wound discomfort, and time away from work and, if positive, will change practice in Canada and around the world.
The Canadian Cancer Trials Group is seeking nominations for the 2020 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Genitourinary Disease Site Committee Executives as well as Supportive Care Committee.
